The aflibercept biosimilar, referencing Eylea, becomes the company’s fifth directly commercialized biosimilar in Europe, expanding access to ophthalmology treatments
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
Yesafili, received marketing authorization approval from the European Commission for the European Union
The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Teva said the launch strengthens its biosimilars strategy and expands access to biologic medicines across Europe
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
